Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

South Korean Pharmas Clamber For Partnerships To Survive Rapidly Changing Environment

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's local pharmas are clambering to tie the knot with multinationals and among themselves in what appears to be a "marriage of necessity" in a desperate attempt to survive a government crackdown on rebates, on which locals have long depended

You may also be interested in...



Fifteen Korean Drug Firms Granted Innovative Status Charged With Unfair Trade Practices

Old habits seem to die hard as 15 Korean pharma companies among 43 granted tax breaks and financial incentives to compete at home and abroad are charged with unfair trade practices, including making rebate payments to secure orders.

Korean Pharma Earnings Roundup: Companies Struggled In First Quarter Because of April Price Cuts And Tightened Regulatory Grip On Rebates

As widely expected, top Korean companies were badly hit during the first quarter by April price cuts and a continuing government crackdown on rebates.

Is M&A The Survival Strategy For Korean Companies? KPMA President Lee Kyeong-Ho Thinks So

Lee Kyeong-Ho, president of the Korea Pharmaceutical Manufacturers Association, expects that local Korean companies will have to pursue M&A to survive a harsh business environment.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC075074

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel